TACTIC-R is a randomised, parallel arm, open-label platform trial for investigating potential treatment for COVID-19 disease. While SARS-CoV infection evades detection by the immune system in the first 24 hours of infection, it ultimately produces a massive immune system response in the subgroup of people who develop severe complications. Most tissue damage following infection with COVID19 appears to be due to a later, exaggerated, host immune response. This leads to lung and sometimes multi-organ damage. Most people who develop these severe complications still have virus present in their respiratory tract at the time-point when the disease starts to evolve. Immune modulation in the presence of active infection has potential to cause more harm than benefit. Safety considerations when studying immune modulation strategies are paramount. Therefore, this study proposes to assess the efficacy of immunomodulatory agents that target dysregulated immune response that drive the severe lung, and other organ, damage. The medications investigated for efficacy in this trial are Baricitinib and Ravulizumab.
TACTIC-R will assess the efficacy of the immunomodulatory agents Baricitinib and Ravulizumab
as potential treatments for COVID-19 disease against Standard of Care alone. These agents
target the dysregulated immune response that drives the severe lung, and other organ, damage
frequently seen during COVID-19 infection. This trial will compare these immunomodulatory
agents to Standard of Care over a 14-day treatment period, with follow-up at 28 and 90 days.
Patients will be randomised in a 1:1:1 ratio across treatments.
TACTIC-R will use a platform design with interim analysis to make efficient decisions about
efficacy and futility (e.g. lack of efficacy and risk of harm) of the trial treatments. This
enables the trial to stop recruiting to arms early where a clear efficacy decision can be
made. It also allows for the addition of further arms.
TACTIC-R will also iterate an algorithm for use of clinical and biochemical phenotyping to:
1. Stratify patients to therapeutic arms according to probability of efficacy
2. Identify early indicators of failure of therapeutic strategy.
By collecting samples for genomics, transcriptomics, proteomics and immunological
phenotyping, parallel studies associated with TACTIC-R will investigate host susceptibility
factors for development of severe COVID-19-related disease and predictive biomarkers of
response to therapeutic strategy.
Drug: Ravulizumab
Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.
Other Name: Ultomiris
Drug: Baricitinib
Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.
Other Name: Olumiant
Other: Standard of care
Regular standard of care for COVID-19 patients
Inclusion Criteria
To be included in the trial the participant must:
1. Be aged 18 and over
2. Have clinical picture strongly suggestive of COVID-19-related (with/without positive
COVID-19 test) AND
- Risk count (as defined below) >3 OR
- ≥ 3 if risk count includes "Radiographic severity score >3"
3. Be considered an appropriate subject for intervention with immunomodulatory in the
opinion of the supervising clinician
4. Be able to be maintained on venous thromboembolism prophylaxis or current maintenance
therapy during inpatient dosing period, according to local guidelines
Exclusion Criteria
The presence of any of the following will preclude participant inclusion:
1. Inability to supply direct informed consent or assent from Next of Kin or Independent
Healthcare Provider on behalf of patient
2. Mechanical ventilation at time of prior to dosing
3. Contraindications to study drugs, including hypersensitivity to the active substances
or any of the excipients
4. Currently on any of the study investigational medicinal products
5. Known unresolved Neisseria meningitidis infection
6. Unwilling to be vaccinated against Neisseria meningitidis or receive prophylactic
antibiotic cover until 2 weeks after vaccination
7. Known active tuberculosis (no blood screening required)
8. Known active Hepatitis B or C (no blood screening required); active varicella zoster
9. Concurrent participation in any interventional clinical trial including
COVID-19-related disease trials (observational studies allowed)
10. Patient moribund at presentation or screening
11. Pregnancy at screening (or unwillingness to adhere to pregnancy advice in protocol)
12. Unwillingness to adhere to breastfeeding advice in protocol
13. Either alanine transaminase or aspartate transaminase (ALT or AST) > 5 times the upper
limit of normal
14. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. Cockcroft Gault
estimated creatinine clearance < 30 ml /min/1.73 m^2)
15. Currently receiving probenecid or chronic IVIG treatment
16. Any medical history or clinically relevant abnormality that is deemed by the principal
investigator and/or medical monitor to make the patient ineligible for inclusion
because of a safety concern.
Risk Count
Patients will be given a Risk Count equal to the cumulative points received for the
following criteria (no = 0 points, yes = 1 point):
Male gender, Age > 40 years, Non-white ethnicity, Diabetes, Hypertension, Neutrophils >
8.0x10^9/L, CRP > 40mg/L, Radiographic severity score >3
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom
Investigator: Elena Hernan Sanch0
Contact: 01223369824
elena.hernansancho@addenbrookes.nhs.uk
Elena Hernan-Sancho
01223 349132 - 349132
elena.hernansancho@addenbrookes.nhs.uk
Frances Hall Hall, FRCP (UK), D.Phil, Principal Investigator
Cambridge University Hospitals NHS Foundation Trust